Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2021 18:54 ET | Source: Genocea Biosciences, Inc.

Genocea to Participate in the B. Riley Securities’ Virtual Oncology Investor Conference

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
January 04, 2021 16:19 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
November 12, 2020 08:00 ET | Source: Genocea Biosciences, Inc.

Genocea to Present at the Stifel 2020 Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
November 09, 2020 08:01 ET | Source: Genocea Biosciences, Inc.

Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020

Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies GEN-011, a neoantigen-targeted peripheral...
November 05, 2020 18:10 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Investor Call Highlighting New GEN-009 Clinical and Immunogenicity Data to be Presented at Virtual SITC 2020

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor...
October 29, 2020 07:00 ET | Source: Genocea Biosciences, Inc.

Genocea Provides Third Quarter 2020 Corporate Update

Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy ...
October 22, 2020 16:57 ET | Source: Genocea Biosciences, Inc.

Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third...
October 14, 2020 17:22 ET | Source: Genocea Biosciences, Inc.

Genocea Announces Upcoming Data Presentations at Virtual SITC 2020

Will showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trial Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the...
September 22, 2020 07:30 ET | Source: Genocea Biosciences, Inc.

Genocea Announces FDA Acceptance of GEN-011 IND Application

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
September 17, 2020 03:00 ET | Source: Genocea Biosciences, Inc.

Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy 100% of patients have immune responses to...